Fig. 5From: Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE studyChange from baseline at Weeks 49–52 in individual VAS scores. *P < 0.001. CI Confidence interval, VAS Visual analogue scaleBack to article page